Healing and stent coverage with the new ultrathin sirolimus-eluting stent with abluminal biodegradable polymer.

Autor: Jun EJ; Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea., Hong SP; Department of Cardiology, School of Medicine, Catholic University of Daegu, Daegu, South Korea., Kim B; Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea., Lee JB; Department of Cardiology, School of Medicine, Catholic University of Daegu, Daegu, South Korea., Shin ES; Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
Jazyk: angličtina
Zdroj: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions [Catheter Cardiovasc Interv] 2023 Nov; Vol. 102 (6), pp. 1040-1047. Date of Electronic Publication: 2023 Oct 19.
DOI: 10.1002/ccd.30871
Abstrakt: Background: Genoss drug-eluting stent (DES) (Genoss Company Limited) is a new ultrathin sirolimus-eluting stent with an abluminal biodegradable polymer and a cobalt-chromium platform.
Aims: The aim of this study was to evaluate vascular healing and neointimal coverage after implantation of the Genoss DES using optical coherence tomography (OCT) 6 months postimplantation.
Methods: From August 22, 2019 to June 17, 2020, this multicenter, observational, investigator-initiated study enrolled 20 patients who underwent OCT examination 6 months after Genoss DES implantation and provided informed consent. An analyst, blinded to the patients' and procedural information analyzed OCT images at an independent core laboratory.
Results: Of the 20 patients, 19 with 27 stents in 21 lesions from 21 vessels were included in the analysis, while one patient withdrew consent and was unwilling to undergo follow-up OCT. OCT analysis was performed 204.4 ± 31.9 days after Genoss DES implantation. A total of 4285 stent struts from 661 cross-sections were analyzed. Strut tissue coverage was observed in 98.7 ± 4.3% of struts, with 0.1 ± 1.2% malapposed struts per lesion. The mean thickness of neointimal hyperplasia (NIH) on the covered struts was 0.12 ± 0.04 mm.
Conclusions: Six months after stent implantation, most Genoss DES struts were covered with a thin layer of NIH that was evenly distributed along the stent length. This pilot study evaluated the outcomes of 6 months dual antiplatelet therapy in the context of ultrathin strut stents, providing insight into developing ethical standards and a scientific foundation for conducting an adequately designed clinical trial.
(© 2023 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: